Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic
  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Advance Drug Discovery with Creative Biolabs’ High-Throughput Screening Solutions

By: Get News
Creative Biolabs uses advanced innovative technology to accelerate drug discovery and research in target-specific therapy for a wide range of diseases, including cancer, genetic disorders, and infectious diseases.

New York, USA - November 25, 2024 - In recent years, the field of RNA therapeutics has emerged as a revolutionary area in biotechnology, offering promising avenues for the treatment of a multitude of diseases, including cancer, genetic disorders, and infectious diseases. Furthermore, as more and more becomes understood about the biology of RNA, its potential for gene therapy becomes obvious, resulting in growing attention by the academic and pharmaceutical sectors. Creative Biolabs has modern services and technologies that assist in the creation of cell therapeutics based on RNA. They focus on high-throughput screening techniques that allow for rapid identification of effective RNA molecules, streamlining the drug discovery process.

SiRNA technology forms an inseparable section of genetics that enables the silencing of cellular regulation mechanisms. Creative Biolabs provides services and capabilities for siRNA screening, which will help select the best siRNA sequences that will downregulate targeted genes most efficiently.

"High-throughput screening in our facility allows us to discover and confirm effective siRNA-modified targets in a timeous manner," said a scientist from this company. "We assist researchers all over the world to carry out their siRNA-based projects and to achieve results that include screening and functional and kinetic analysis of the chosen targets."

Antisense oligonucleotides (ASOs) can be designed to treat a broad range of genetic diseases. Creative Biolabs assists researchers by providing ASO Screening services that allow them to design suitable ASO sequences for gene expression modulation. Enhanced screening technologies allow the development of AO therapeutics with relative ease, precision and efficacy. From sequence design to acquisition of AO with desired anti-sense activity, their practice provides expertise in all aspects of ASO development.

In addition to RNA-based solutions, Creative Biolabs has wide experience in aptamer design and provides custom solutions to fit the specific requirements of each project.

"Aptamers are molecular tools that are specially engineered for use in diagnostics, therapeutics, and other areas. Our patented aptamer selection and optimization procedures ensure the discovery of aptamers with excellent affinity and specificity. With our expertise, researchers are in a position to design aptamers that bind selectively to specific types of molecules," emphasized the scientist.

As a trusted partner in therapeutics development, Creative Biolabs is dedicated to offering innovative and tailored solutions for our customers to ensure the effects of their projects. Their mission is to provide strong support to customers' research projects with expertise and cutting-edge development platforms.

Learn more information about services regarding RNA therapeutics research, please visit https://www.creative-biolabs.com/gene-therapy.

About Creative Biolabs

Creative Biolabs is a biotechnology company based in US, focusing on the development of efficient solutions for biomedical studies and drug discovery and development. With the commitment to advancing RNA therapeutics, the company delivers siRNA screening, ASO screening, and aptamer design services to enhance customers' research projects for new therapies.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/gene-therapy

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.